Long Covid is a living hell – but I’ve finally found a solution
Key findings:
- The experimental PGV001 vaccine in combination with an immunotherapy drug was safe and well-tolerated, with only mild injection-site reactions.
- All tested patients developed new, vaccine-specific T cell responses not seen before treatment.
- The personalized vaccine approach proved feasible both for patients with metastatic disease and those receiving treatment after surgery.
David Putrino, PhD, discusses long COVID, what the symptoms are, and what treatment looks like. Learn more.
